JPMorgan Chase & Co. Forecasts Strong Price Appreciation for DexCom (NASDAQ:DXCM) Stock

DexCom (NASDAQ:DXCM) had its price target boosted by equities researchers at JPMorgan Chase & Co. from $82.00 to $85.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 3.29% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. BTIG Research raised their target price on shares of DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Wells Fargo & Company lifted their price objective on DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Citigroup restated a “buy” rating and set a $88.00 target price (up from $84.00) on shares of DexCom in a research report on Friday, July 31st. Argus boosted their target price on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, Piper Sandler reiterated an “overweight” rating and set a $95.00 price target (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Buy” and an average price target of $92.91.

DexCom Price Performance

Shares of DXCM stock traded up $2.36 during trading hours on Friday, hitting $82.29. 8,637,222 shares of the company’s stock were exchanged, compared to its average volume of 5,033,590. DexCom has a fifty-two week low of $54.11 and a fifty-two week high of $92.59. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The firm has a 50 day moving average of $85.98 and a two-hundred day moving average of $74.60. The firm has a market cap of $31.05 billion, a P/E ratio of 32.53, a P/E/G ratio of 1.32 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.05. The firm had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.61 EPS. Sell-side analysts forecast that DexCom will post 2.64 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, Director Mark G. Foletta sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the transaction, the director owned 48,852 shares in the company, valued at $4,168,052.64. This trade represents a 3.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction on Monday, September 28th. The stock was sold at an average price of $86.15, for a total value of $220,974.75. Following the sale, the executive vice president owned 123,478 shares of the company’s stock, valued at approximately $10,637,629.70. This trade represents a 2.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 24,822 shares of company stock worth $2,090,833 over the last three months. 0.28% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On DexCom

Institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in DexCom by 15.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock worth $758,487,000 after acquiring an additional 1,515,702 shares during the period. Legal & General Group Plc acquired a new position in shares of DexCom in the second quarter worth $173,237,000. Janus Henderson Group PLC boosted its holdings in shares of DexCom by 32.3% in the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after purchasing an additional 645,534 shares during the last quarter. Deutsche Bank AG purchased a new position in DexCom in the 2nd quarter valued at about $164,035,000. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of DexCom by 100.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock worth $159,832,000 after buying an additional 1,275,142 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.